Seres Therapeutics Stock Alpha and Beta Analysis
| MCRB Stock | USD 0.86 0.05 6.17% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Seres Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Seres Therapeutics over a specified time horizon. Remember, high Seres Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Seres Therapeutics' market risk premium analysis include:
Beta 1.33 | Alpha 0.19 | Risk 6.71 | Sharpe Ratio 0.041 | Expected Return 0.28 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Seres |
Seres Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Seres Therapeutics market risk premium is the additional return an investor will receive from holding Seres Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Seres Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Seres Therapeutics' performance over market.| α | 0.19 | β | 1.33 |
Seres Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Seres Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Seres Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Seres Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Seres Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Seres Therapeutics shares will generate the highest return on investment. By understating and applying Seres Therapeutics stock market price indicators, traders can identify Seres Therapeutics position entry and exit signals to maximize returns.
Seres Therapeutics Return and Market Media
The median price of Seres Therapeutics for the period between Fri, Nov 1, 2024 and Thu, Jan 30, 2025 is 0.82 with a coefficient of variation of 11.86. The daily time series for the period is distributed with a sample standard deviation of 0.1, arithmetic mean of 0.81, and mean deviation of 0.08. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Von Moltke Lisa of 2969 shares of Seres Therapeutics subject to Rule 16b-3 | 11/01/2024 |
2 | Acquisition by Von Moltke Lisa of 287905 shares of Seres Therapeutics at 1.1 subject to Rule 16b-3 | 11/11/2024 |
3 | Little Excitement Around Seres Therapeutics, Inc.s Revenues As Shares Take 30 percent Pounding | 11/15/2024 |
4 | Disposition of 927 shares by Matthew Henn of Seres Therapeutics at 0.5407 subject to Rule 16b-3 | 11/18/2024 |
5 | Seres Therapeutics CEO Eric Shaff sells shares worth 1,354 | 11/19/2024 |
6 | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics SER-155 for Reduction of ... | 12/09/2024 |
7 | The past three years for Seres Therapeutics investors has not been profitable | 12/26/2024 |
8 | Seres Therapeutics Announces Receipt of Expected 50 Million Installment Payment Related to ... | 01/16/2025 |
9 | Microbiomes Market to Grow by USD 1.13 Billion , Driven by Rising Disease Prevalence AI Impact on Market Trends - Technavio | 01/17/2025 |
10 | Disposition of 878 shares by Desrosier Thomas of Seres Therapeutics at 0.5407 subject to Rule 16b-3 | 01/24/2025 |
About Seres Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Seres or other stocks. Alpha measures the amount that position in Seres Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Graham Number | 3.04 | 2.89 | Receivables Turnover | 16.75 | 13.73 |
Seres Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Seres Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seres Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Seres Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Seres Therapeutics. Please utilize our Beneish M Score to check the likelihood of Seres Therapeutics' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Seres Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Seres Therapeutics Backtesting, Seres Therapeutics Valuation, Seres Therapeutics Correlation, Seres Therapeutics Hype Analysis, Seres Therapeutics Volatility, Seres Therapeutics History and analyze Seres Therapeutics Performance. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Seres Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.